首页> 外文期刊>Journal of Clinical Oncology >Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study.
【24h】

Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study.

机译:射频热消融结直肠癌转移至肝脏后的生存预测因素:一项前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE The aim of this study was to determine the predictors of survival at the time of radiofrequency thermal ablation (RFA) in patients with colorectal liver metastasis. PATIENTS AND METHODS One hundred thirty-five patients with colorectal liver metastases who were not candidates for resection underwent laparoscopic RFA. Results The median Kaplan-Meier survival for all patients was 28.9 months after RFA treatment. Patients with a carcinoembryonic antigen (CEA) less than 200 ng/mL had improved survival compared with those with a CEA more than 200 (34 v 16 months; P = .01). Patients with the dominant lesion less than 3 cm in diameter had a median survival of 38 v 34 months for lesions 3 to 5 cm, and 21 months for lesions greater than 5 cm (P = .03). Survival approached significance for patients with one to three tumors versus more than three tumors (29 v 22 months; P = .09). The presence of extrahepatic disease did not affect survival. Only the largest liver tumor size more than 5 cm was found to be asignificant predictor of mortality by Cox proportional hazards model, with a 2.5-fold increased risk of death versus the largest liver tumor size less than 3 cm (P = .05). CONCLUSION This study determines which patients do best after RFA. Historical survival with chemotherapy alone is 11 to 14 months, suggesting RFA has a positive impact on overall survival. Limited amounts of extrahepatic disease do not appear to affect survival adversely. RFA is a useful adjunct to chemotherapy in those patients with liver-predominant disease.
机译:目的本研究的目的是确定大肠肝转移患者射频热消融(RFA)时生存的预测指标。患者与方法135例不适合切除的大肠肝转移患者接受了腹腔镜RFA检查。结果RFA治疗后所有患者的中位Kaplan-Meier生存期为28.9个月。癌胚抗原(CEA)低于200 ng / mL的患者相比CEA高于200的患者(34 v 16个月; P = 0.01)具有更高的生存率。直径小于3 cm的主要病变患者的中位生存期为3到5 cm的中位生存期分别为38个月和34个月,大于5 cm的中位生存期为21个月(P = .03)。对于具有一到三个肿瘤而不是三个以上肿瘤的患者,生存率具有重要意义(29 v 22个月; P = .09)。肝外疾病的存在并不影响生存。根据Cox比例风险模型,只有最大的肝肿瘤尺寸大于5 cm才是死亡率的重要预测指标,而最大的肝肿瘤尺寸小于3 cm则死亡风险增加了2.5倍(P = 0.05)。结论本研究确定了RFA后哪些患者表现最好。单纯化疗的历史生存时间为11至14个月,这表明RFA对总体生存具有积极影响。数量有限的肝外疾病似乎对生存没有不利影响。对于患有肝癌的患者,RFA是化疗的有用辅助手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号